Pages

• About Zealand
  • About Us
  • Board of Directors
  • Corporate Governance
    • Audit Committee
    • Nomination Committee
    • Remuneration Committee
    • Scientific Committee
  • Corporate Management
  • Corporate Social Responsibility
  • Disease Focus
    • Gastrointestinal (GI) Diseases
      • Marianne’s Story
      • Mike’s Story
      • Will’s Story
    • Metabolic Diseases
      • Crosby’s Story
  • History
  • Strategy
  • Transparency Reporting
  • Videos About Zealand
• Careers
  • Disclaimer: Beware of Recruitment Fraud
  • Meet Us
  • Personal Data in the Recruitment Process
  • Positions
  • Zealand as a Workplace
• Contact
• Home
• Investor
  • Analyst Coverage
  • Annual General Meeting
  • Corporate Presentation
  • Corporate Presentation (PDF)
  • Events
  • Financial Calendar
  • Financial Reports
    • Financial Reports for 2014
    • Financial Reports for 2015
    • Financial Reports for 2016
    • Financial Reports for 2017
    • Financial Reports for 2018
    • Financial Reports for 2019
    • Financial Reports for 2020
    • Financial Reports for 2021
    • Financial Reports for 2022
  • Investor Relations
  • Newsletter Signup
  • Prospectus
  • SEC Filings
  • Shareholder Portal
  • Stock Information
• Legal Disclaimer
• Media
  • Downloads
  • Media Inquiry
  • Zealand News
• Privacy Policy
• R&D
  • Amylin Analogue, ZP8396 for Obesity
  • BI 456906 GLP-1/Glucagon Dual Agonist (obesity, NASH, diabetes)
  • Dasiglucagon for Bi-Hormonal Artificial Pancreas Systems
  • Dasiglucagon for Congenital Hyperinsulinism
  • Glepaglutide for Short Bowel Syndrome
  • In-licensing
  • Our Focus on Peptide-Based Medicines
  • Peptide Platform Video
  • Product Pipeline
  • What are Peptides